Scarica l'app Stockscreener
25.57
0.89%
0.2386
Precedente Chiudi:
$25.33
Aprire:
$25.59
Volume 24 ore:
85,044
Relative Volume:
0.28
Capitalizzazione di mercato:
$1.77B
Reddito:
$751.00K
Utile/perdita netta:
$-74.57M
Rapporto P/E:
-23.18
EPS:
-1.1031
Flusso di cassa netto:
$-54.46M
1 W Prestazione:
+3.58%
1M Prestazione:
+33.93%
6M Prestazione:
+89.43%
1 anno Prestazione:
+49.44%
Intervallo 1D:
$25.30
$26.30
Intervallo di 1 settimana:
$23.60
$28.53
Portata 52W:
$12.56
$28.53
Pulse Biosciences Inc Stock (PLSE) Company Profile
Nome
Pulse Biosciences Inc
Settore
Industria
Telefono
510-906-4600
Indirizzo
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, RMD, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
25.51 | 1.75B | 751.00K | -74.57M | -54.46M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
419.36 | 149.48B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
150.19 | 41.65B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.29 | 32.58B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
193.58 | 28.44B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
33.42 | 28.42B | 29.14B | 1.07B | 1.05B | 1.1956 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | Mizuho | Outperform |
| 2025-07-07 | Iniziato | Oppenheimer | Outperform |
| 2021-07-27 | Iniziato | Stephens | Overweight |
| 2021-03-11 | Iniziato | Maxim Group | Buy |
| 2021-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-12 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Pulse Biosciences Inc Borsa (PLSE) Ultime notizie
Does Pulse Biosciences’ (PLSE) Insider Buying Reinforce Canaccord’s Cardiac PFA Thesis or Raise New Questions? - Sahm
Pulse Biosciences board approves affiliate participation in equity sales program - Investing.com
Pulse Biosciences (PLSE) Initiated with Buy Rating and $32 Targe - GuruFocus
Canaccord initiates Pulse Biosciences stock with buy on ablation tech - Investing.com UK
PLSE Initiates Coverage On by Canaccord Genuity -- Price Target Set at $32 - GuruFocus
Canaccord initiates Pulse Biosciences stock with buy on ablation tech By Investing.com - Investing.com Nigeria
Canaccord Genuity Initiates Pulse Biosciences at Buy With $32 Price Target - marketscreener.com
CCORF Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $32 - Moomoo
Here's why Pulse Biosciences, Inc (PLSE) is a great momentum stock to buy - MSN
Discipline and Rules-Based Execution in PLSE Response - Stock Traders Daily
PLSE Technical Analysis & Stock Price Forecast - Intellectia AI
PLSE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pulse Biosciences (PLSE) Valuation Check After Strong Recent Share Price Momentum - Sahm
PLSE Q1 2026 Earnings: EPS Beat but No Revenue as Stock DeclinesEarnings Miss Alert - thelegaladvocate.com
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - BioSpace
Pulse Biosciences (PLSE) Holds Steady: Key Levels in FocusButterfly Setup - The Legal Advocate
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy - Yahoo Finance
Pulse Biosciences Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Pulse Biosciences (PLSE) Rises Modestly as Shares Test Key ResistanceTICK Divergence - The Legal Advocate
Assessing Pulse Biosciences (PLSE) Valuation After Recent Share Price Surge - Sahm
Pulse Biosciences Begins nPulse Study for Malignant Thyroid Tumor Treatment - Medical Product Outsourcing
Pulse Biosciences Earnings Call Highlights Clinical Momentum - TipRanks
Behavioral Patterns of PLSE and Institutional Flows - Stock Traders Daily
Pulse Biosciences, IncCommon Stock (NQ: PLSE - The Chronicle-Journal
PLSE accelerates cardiac catheter program after breakthrough AFib data - MSN
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors. - The Globe and Mail
Pulse Biosciences CEO Buys 15,000 Shares: SEC Filing Details | May 2026News and Statistics - IndexBox
(SEC Amendment) Pulse Biosciences(PLSE.US) 10% Shareholder Buys US$13 Million in Common Stock - Moomoo
Pulse Biosciences director Robert W. Duggan acquires $13m in stock - Investing.com Nigeria
Pulse Biosciences director Robert W. Duggan acquires $13m in stock By Investing.com - Investing.com South Africa
Director Robert Duggan buys 660K Pulse Biosciences (PLSE) shares - Stock Titan
Pulse Bio rises after over $13M insider buying - MSN
Pulse Biosciences stock hits 52-week high at 26.33 USD By Investing.com - Investing.com Nigeria
Pulse Biosciences, Inc. Q1 2026 Financial Report – Revenue, Losses, and Key Corporate Updates - Minichart
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System Study - Medical Product Outsourcing
Pulse Biosciences stock hits 52-week high at 26.33 USD - Investing.com India
Pulse Biosciences stock (US73242P1030): Q1 2026 net loss widens to $18.6M on early commercialization - AD HOC NEWS
PULSE BIOSCIENCES, INC. 1Q 2026: Revenue $401K, EPS ($0.27) — 10-Q Summary - TradingView
Pulse Biosciences (NASDAQ: PLSE) Q1 2026 results, cash burn and AF strategy - Stock Titan
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026Slideshow - Seeking Alpha
[SCHEDULE 13D/A] PULSE BIOSCIENCES, INC. Amended Major Shareholder Report - Stock Titan
Pulse Biosciences Insider Bought Shares Worth $12,999,988, According to a Recent SEC Filing - Moomoo
Pulse Biosciences Inc Azioni (PLSE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pulse Biosciences Inc Azioni (PLSE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
0.55%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):